Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fleming, Evelyn
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer	Terminated	3	20	Canada, US, RoW	Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo	Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)	High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	09/23	09/23
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer	Active, not recruiting	2	51	US	Ribociclib, Letrozole	Gynecologic Oncology Group, Novartis	Low Grade Serous Carcinoma	12/23	12/24
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer From a trial for solid tumors Jun 2020 - Jun 2020: From a trial for solid tumors	Active, not recruiting	1	146	US	RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed	Inspirna, Inc.	Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma	12/24	12/24
Kihwele, Jacqueline M
No trials found